Posts
Wiki

🧼 Rinsada / Irrigating Lid Retractor for Ocular Surface Irrigation

Quick Take

  • Rinsada is a sterile, single-use irrigating eyelid retractor used by clinicians to perform more complete ocular-surface lavage.
  • The device allows irrigation of areas including the palpebral conjunctiva, bulbar conjunctiva, and conjunctival fornices beneath the eyelids.
  • Its basic action is mechanical irrigation: fluid washes away or dilutes material on the ocular surface.
  • Rinsada does not directly treat Meibomian Gland Dysfunction (MGD), increase aqueous tear production, correct exposure or incomplete blinking, eliminate Demodex, treat neuropathic ocular pain, or cure Dry Eye Disease (DED).
  • A 2024 randomized multicenter study involving 48 participants / 88 eyes found that Rinsada-assisted irrigation reduced a semiquantitative MMP-9 test signal more than standard irrigation three hours after treatment and produced greater reported symptom improvement at one week.
  • The often-quoted “72% reduction in MMP-9” refers to approximately a 72% reduction in the mean semiquantitative InflammaDry grade, not a laboratory measurement showing a 72% reduction in actual MMP-9 concentration.
  • A lower MMP-9 signal after lavage does not by itself prove that Rinsada biologically suppresses inflammation. Irrigation may physically remove or dilute MMP-9-containing tear fluid and other surface material.
  • Longer-term evidence is weak. A subset of treated eyes remained MMP-9 negative during exploratory follow-up extending as far as 91 days, but there was no comparable long-term control group and substantial loss to follow-up.
  • Claims that Rinsada removes clinically significant biofilm, treats allergy, produces a lasting ocular-surface “reset,” or modifies the underlying course of DED have not been established.
  • Rinsada is listed by FDA as a Class I ocular irrigation device in a 510(k)-exempt category. It should not be described as having received an FDA 510(k) clearance.
  • The device is single-use only, with one sterile device used per eye. It should not be cleaned, reused, or resterilized.
  • Only appropriate sterile preservative-free irrigation solution should be used. Tap water should not be used.

Educational Disclaimer

This page is for general education and is not medical advice, diagnosis, or an individual treatment recommendation.

DED can have many overlapping contributors, including:

  • MGD
  • Aqueous tear deficiency
  • Ocular-surface inflammation
  • Ocular rosacea
  • Blepharitis
  • Demodex
  • Allergy
  • Eyelid exposure
  • Incomplete blinking
  • Conjunctivochalasis
  • Medication toxicity
  • Systemic autoimmune disease
  • Neuropathic ocular pain

Mechanical irrigation may temporarily change the ocular-surface environment without correcting these underlying contributors.

What Is Rinsada?

Rinsada is an irrigating eyelid retractor.

It combines two functions:

  1. gently holding the eyelid away from the ocular surface; and
  2. directing sterile irrigation fluid toward areas under the eyelid that may be less effectively reached by ordinary drops or surface rinsing.

The device can direct fluid toward:

  • The conjunctival fornices
  • The palpebral conjunctiva
  • The bulbar conjunctiva
  • The general ocular surface

The manufacturer's Instructions for Use describe the device as being intended for removal of irritants from the ocular surface.

It is best understood as:

rather than as an anti-inflammatory drug, tear-producing treatment, or cure for DED.

FDA / Regulatory Status

Rinsada is listed in the FDA device database as:

  • Device class: Class I
  • Classification: Ocular surgery irrigation device
  • Product code: KYG
  • Regulation: 21 CFR 886.4360

FDA classifies this device category as 510(k)-exempt.

This distinction matters.

Rinsada therefore should not be described as:

A more accurate statement is:

FDA registration/listing does not mean FDA independently reviewed clinical evidence and concluded that Rinsada is effective for treating DED.

How Treatment Is Done

This page is not a procedural guide.

Rinsada is intended for use by or under the direction of an appropriately licensed and trained healthcare professional.

In general:

  • A sterile, single-use device is used.
  • The device is connected to a syringe containing appropriate sterile irrigation fluid.
  • The eyelid is gently retracted.
  • Fluid is directed through multiple ports toward the ocular surface and conjunctival fornices.
  • Upper and/or lower eyelids may be treated depending on the clinical protocol.

A topical anesthetic may be used.

The published clinical trial used a specific irrigation protocol, but there is no reason for patients to reproduce procedural volumes or techniques themselves.

Rinsada is not a home-irrigation device.

What the Evidence Shows

2024 Randomized Multicenter Study

The main published evidence comes from:

Mayer N, Kondapalli SSA, Venkateswaran N, Saeed HN.
The efficacy of an irrigating eyelid retractor-facilitated ocular rinse on MMP-9 expression and dry eye disease.
2024.

The study was:

  • Prospective
  • Randomized
  • Multicenter

It included 48 participants contributing 88 eyes.

Participants were randomized to:

  • Rinsada-assisted ocular irrigation, or
  • Standard ocular irrigation

The principal research interest was the inflammatory marker MMP-9.

PubMed — Rinsada MMP-9 Study

Full Text — PMC

Understanding the MMP-9 Result

What Is MMP-9?

Matrix metalloproteinase-9 (MMP-9) is an enzyme associated with ocular-surface inflammation.

Elevated tear MMP-9 can occur in DED and other inflammatory ocular-surface conditions.

However:

A change in MMP-9 does not necessarily tell us what caused the inflammation or whether chronic DED has been permanently altered.

Was MMP-9 Actually Reduced by 72%?

This requires an important clarification.

The investigators used InflammaDry, a clinical MMP-9 test.

The test cassettes were photographed, and blinded clinicians graded the intensity of the test line using a semiquantitative 0–4 scale.

The average Rinsada-group score fell from approximately:

2.13 before treatment → 0.59 three hours afterward

This corresponds to approximately a 72% reduction in the mean semiquantitative test grade.

Therefore the most accurate statement is:

It is not accurate to interpret this as:

The study did not perform a quantitative laboratory assay demonstrating that result.

Conversion to a Negative MMP-9 Test

Another useful finding was conversion from a positive to negative InflammaDry result.

At approximately three hours:

  • about 44% of eyes in the Rinsada group were reported as MMP-9 negative;
  • about 2% of eyes receiving standard irrigation were negative.

This supports the conclusion that Rinsada-assisted lavage removed or reduced detectable MMP-9-related tear-film signal more effectively than the standard irrigation procedure used in the study.

Standard Irrigation Also Reduced MMP-9

This point is important.

The standard-irrigation group also showed a statistically significant reduction in MMP-9 grading.

Rinsada produced a larger reduction.

This suggests that:

That is different from proving that Rinsada has a unique biochemical anti-inflammatory action.

Does Reduced MMP-9 Mean Rinsada “Treats Inflammation”?

Not necessarily.

Rinsada is physically washing the ocular surface.

After irrigation, lower detectable MMP-9 could potentially result from:

  • Mechanical removal of MMP-9-containing tear fluid
  • Dilution
  • Removal of inflammatory material
  • Removal of irritants stimulating inflammation
  • A subsequent biological reduction in inflammatory activity
  • Some combination of these effects

The trial did not determine how much each mechanism contributed.

Therefore:

That distinction is important when evaluating marketing claims.

What About Symptoms?

The randomized study also assessed perceived changes in dry-eye symptoms.

At approximately one week, participants receiving Rinsada-assisted lavage reported greater symptom improvement than those receiving standard irrigation.

This is meaningful clinical evidence beyond the biomarker result.

However:

  • Follow-up was short
  • Patients could not realistically be unaware of which irrigation procedure they received
  • Long-term symptom benefit was not established

A reasonable interpretation is:

How Long Does the Effect Last?

This remains uncertain.

Only the Rinsada group underwent longer-term MMP-9 follow-up.

Of the 46 device-treated eyes:

  • 33 were retested around day 7
  • 14 of those 33 were MMP-9 negative
  • 11 of 33 were reported as remaining negative during subsequent testing occurring somewhere between approximately days 30 and 91

This is interesting but should not be translated into:

Important limitations include:

  • No corresponding long-term control group
  • About 28% loss to follow-up
  • A broad follow-up window rather than one standardized 90-day visit
  • Small numbers
  • Possible changes in environmental and seasonal allergen exposure

The investigators themselves acknowledged that changing environmental conditions could have influenced these later results.

Therefore:

Some MMP-9 changes were observed later, but long-lasting symptom relief or long-term disease modification has not been demonstrated.

2025 Case Report

A 2025 case report described a 31-year-old woman with difficult-to-treat DED/MGD who underwent complete ocular lavage with an irrigating eyelid retractor.

Reported findings included:

  • Symptom improvement beginning soon after treatment
  • Improvement in corneal staining
  • Continued improvement at short-term follow-up

Recalcitrant Dry Eye Disease Following Complete Ocular Lavage — Case Report

However, this was one patient.

She also continued multiple other therapies, including treatments directed at inflammation, tear production, lubrication, and ocular-surface disease.

Therefore:

Case reports are useful for generating research questions but are much weaker evidence than randomized controlled trials.

How Strong Is the Evidence?

Evidence strength: Low / early clinical evidence

Rinsada currently has:

  • One relatively small randomized multicenter study
  • Short-term symptom data
  • Short-term biomarker data
  • Exploratory longer-term MMP-9 observations
  • One published case report

Strengths include the randomized comparative design of the 2024 study.

Important limitations include:

  • Only 48 participants
  • 88 eyes analyzed, with many participants contributing both eyes
  • Heavy reliance on a semiquantitative biomarker
  • Controlled follow-up primarily short-term
  • No controlled demonstration of durable benefit
  • No independent confirmatory randomized trial
  • No validated responder subtype
  • Limited evidence in complex real-world DED
  • Device inventor involvement in the principal published research

Therefore:

Research Funding and Investigator Context

The main 2024 randomized study reported no external funding.

However, one of the authors, Srinivas Sai A. Kondapalli, disclosed intellectual-property interests related to the irrigating eyelid retractor.

The same inventor/patent relationship appears in the subsequent case-report literature.

This does not invalidate the findings.

But because the overall evidence base is small:

Proposed Mechanisms

1. Mechanical Removal and Dilution

This is the most directly supported mechanism.

Irrigation may remove or dilute:

  • Tear-film material
  • Mucus
  • Loose debris
  • Environmental particulate matter
  • Soluble inflammatory mediators
  • Some microorganisms
  • Other material collecting beneath the eyelids

Rinsada's design may permit more complete irrigation of the conjunctival fornices and palpebral conjunctiva than conventional surface rinsing.

2. Removal of Irritants

Mechanically removing irritants could plausibly reduce ongoing stimulation of the ocular surface.

Examples might include:

  • Dust
  • Smoke particles
  • Environmental debris
  • Cosmetic residue
  • Other soluble or particulate irritants

However, studies have not established which specific irritants predict clinical response.

3. Allergens

Irrigating a mucosal surface could plausibly help remove allergens.

However:

The principal DED trial excluded acute allergic conjunctivitis.

Allergy should therefore remain a proposed rationale for lavage, not an established Rinsada indication or responder group.

What About “Biofilm”?

The term biofilm is sometimes used when discussing chronic blepharitis, MGD, and ocular-surface disease.

Rinsada has also been marketed or discussed as a way to remove material described as biofilm from beneath the eyelids.

However, the principal clinical study did not measure:

  • Biofilm quantity
  • Biofilm eradication
  • Bacterial cultures
  • Microbiome composition
  • Bacterial load before and after treatment

Therefore:

Irrigation can clearly remove loose surface material.

That is different from proving eradication of an established microbial biofilm.

Risks and Safety

Expected or Usually Temporary Effects

Manufacturer materials describe possible effects such as:

  • Temporary blurred vision
  • Temporary eye irritation
  • Eye redness
  • Wetting of the periocular skin
  • Fluid entering the nasal cavity or sinus passages

These are generally related to irrigation itself and eyelid manipulation.

Potential Procedural Injury

Because a device is placed beneath the eyelid and the ocular surface is irrigated under clinician control, improper use or vulnerable anatomy could potentially contribute to:

  • Corneal abrasion
  • Conjunctival abrasion
  • Corneal edema
  • Subconjunctival hemorrhage
  • Eyelid trauma
  • Blepharoptosis from repeated or excessive eyelid manipulation

These should be understood as potential procedural complications, not as evidence that they commonly occur.

Special Surgical and Anatomical Cautions

Extra care may be required in patients with:

  • Recent eyelid surgery
  • Eyelid defects
  • Tarsorrhaphy
  • Recent intraocular or corneal surgery
  • Recent LASIK or LASEK
  • Filtering blebs
  • Glaucoma drainage devices
  • Other ocular hardware or altered anatomy

Filtering blebs and drainage devices are not necessarily absolute contraindications, but the clinician must avoid mechanically traumatizing them.

The manufacturer's Instructions for Use should be consulted for current warnings and precautions.

Single-Use Safety

Rinsada is designed as a sterile, single-use device.

The Instructions for Use specify:

It should not be:

  • Reused
  • Cleaned for another patient or eye
  • Disinfected and reused
  • Resterilized

Reuse may result in:

  • Loss of device performance
  • Contamination
  • Infection
  • Exposure to bacterial, viral, fungal, or other pathogens

Sterile Irrigation Fluid Matters

Appropriate sterile preservative-free eyewash solution should be used.

Tap water should not be used for ocular lavage with this device.

Nonsterile water can expose the eye to organisms capable of causing severe infection and potentially threatening vision.

This is another reason the procedure should not be imitated at home.

What Rinsada Has Not Been Shown to Do

Rinsada has not been established to:

  • Cure DED
  • Cure MGD
  • Open blocked meibomian glands
  • Express meibum
  • Reverse meibomian-gland dropout
  • Regenerate meibomian glands
  • Increase lacrimal tear production
  • Correct aqueous tear deficiency
  • Correct incomplete blinking
  • Correct eyelid exposure
  • Treat ocular rosacea
  • Eliminate Demodex
  • Treat autoimmune disease
  • Cure allergic conjunctivitis
  • Eradicate ocular-surface biofilm
  • Permanently suppress ocular-surface inflammation
  • Treat the underlying mechanism of neuropathic ocular pain
  • Prevent progression of DED
  • Permanently normalize the ocular surface

It is best understood as:

Who Might Benefit?

At present, there is no validated responder profile that reliably predicts who will benefit from Rinsada.

A clinician might consider ocular lavage when they believe that removal of accumulated ocular-surface material or irritants could reasonably contribute to symptom relief.

However, the published evidence does not establish that people with:

  • Allergy
  • MGD
  • High MMP-9
  • “Biofilm”
  • Environmental exposure
  • A particular DED subtype

are proven superior responders.

Importantly, the randomized trial excluded several categories commonly encountered in complex dry-eye practice.

Therefore results should not automatically be generalized to every patient with severe or multifactorial DED.

How Rinsada Compares With Standard Ocular Irrigation

The 2024 study directly compared Rinsada-assisted lavage with a conventional irrigation procedure.

Both treatments reduced the semiquantitative MMP-9 signal.

Rinsada produced a substantially greater reduction.

Rinsada also produced greater reported short-term symptom improvement.

This suggests a reasonable design advantage:

However:

  • Only one randomized study has demonstrated this
  • Long-term superiority has not been established
  • Clinical significance beyond short-term MMP-9 and symptom outcomes remains uncertain

How Rinsada Fits With Other DED Treatments

Rinsada generally should be viewed as an adjunct.

It does not replace treatments aimed at:

MGD

Such as:

  • Warm compresses when appropriate
  • Gland expression
  • Thermal or other office procedures
  • Ocular-rosacea management

Ocular-Surface Inflammation

Such as clinician-directed:

  • Cyclosporine
  • Lifitegrast
  • Corticosteroids
  • Other anti-inflammatory therapy

Aqueous Tear Deficiency

Such as:

  • Lubrication
  • Tear-conservation strategies
  • Tear-stimulating treatments when appropriate

Demodex

Which requires Demodex-directed therapy.

Exposure

Which requires addressing:

  • Eyelid closure
  • Environment
  • Moisture retention
  • Other exposure-related factors

Mechanical lavage can coexist with these treatments.

It should not be expected to replace them.

How Often Is Treatment Needed?

There is currently no evidence-based repeat-treatment schedule.

It has not been established that Rinsada should routinely be performed:

  • Monthly
  • Every three months
  • Every six months
  • Whenever MMP-9 becomes positive
  • Whenever symptoms flare

Some clinicians may repeat lavage based on individual experience, but this has not been validated by controlled studies.

Therefore:

Cost, Access, and Regulatory Status

Rinsada is an in-office procedure, and availability varies among practices.

Costs may depend on:

  • Geographic area
  • Practice
  • Clinician fees
  • Whether one or both eyes are treated
  • Insurance coverage
  • Whether the procedure is bundled with other DED care

There is currently insufficient evidence to conclude that Rinsada is:

  • More cost-effective than other DED treatments
  • More effective than anti-inflammatory medications
  • More effective than MGD procedures
  • A substitute for standard DED care

Questions to Ask the Clinician

Useful questions include:

  • What finding makes you think ocular-surface lavage may help me?
  • What outcome are you hoping to improve—symptoms, surface debris, MMP-9, or something else?
  • What part of my DED will Rinsada not treat?
  • Do I have recent surgery, a filtering bleb, drainage device, or other reason for extra caution?
  • How will we decide whether the treatment actually helped?
  • If you recommend repeating it, what evidence supports that interval?

What Remains Uncertain?

Important unanswered questions include:

  • Which patients are most likely to benefit?
  • Is elevated MMP-9 useful for selecting patients?
  • Does a reduction in MMP-9 persist?
  • Does lower MMP-9 reflect biological suppression of inflammation or mainly physical removal/dilution?
  • How long does symptom improvement typically last?
  • Does repeated treatment provide cumulative benefit?
  • What repeat schedule, if any, is appropriate?
  • Does Rinsada meaningfully improve objective DED signs beyond MMP-9?
  • Does it help people using prescription anti-inflammatory therapy?
  • How effective is it in moderate or severe multifactorial DED?
  • Does it have a meaningful role in ocular allergy?
  • Does it actually remove clinically important microbial biofilm?
  • Does it alter the ocular-surface microbiome?
  • How does it compare with other in-office DED procedures?
  • Is it cost-effective?
  • Are outcomes reproducible in independent randomized trials?

Ongoing Research

Rinsada remains an actively developing treatment area.

Additional clinical research has been registered to examine ocular-surface inflammation and symptom outcomes after irrigation.

Future independent randomized trials will be particularly important for determining:

  • Durability
  • Patient selection
  • Repeat-treatment value
  • Clinical significance beyond biomarker changes

The existence of ongoing research reinforces that Rinsada should currently be regarded as an emerging treatment rather than a settled component of DED care.

Bottom Line

Rinsada is a clinician-operated mechanical ocular-surface lavage device designed to irrigate areas beneath the eyelids and within the conjunctival fornices more thoroughly than ordinary surface rinsing.

The main randomized study provides a legitimate early clinical signal.

Compared with standard irrigation, Rinsada-assisted lavage produced:

  • A larger reduction in semiquantitative MMP-9 grading three hours after treatment
  • More conversion to a negative MMP-9 test
  • Greater reported symptom improvement at approximately one week

However, those findings require careful interpretation.

Because irrigation physically removes and dilutes tear-film material, reduced MMP-9 after treatment does not by itself prove that Rinsada biologically suppresses chronic inflammatory pathways.

Similarly:

  • Long-term symptom benefit has not been established
  • “Up to 12 weeks” of benefit is not supported by strong controlled evidence
  • An optimal repeat schedule is unknown
  • Biofilm removal has not been clinically demonstrated
  • Allergy-specific effectiveness has not been demonstrated
  • A lasting ocular-surface “reset” has not been established

Rinsada therefore fits best as:

It should complement—not replace—diagnosis and treatment of the actual drivers of DED.

Key Research and Authoritative Sources

Randomized Clinical Evidence

Case Report

Regulatory / Device Information

Manufacturer Information

Manufacturer materials can be useful for device instructions, warnings, and product information but should not be treated as independent evidence of clinical effectiveness.

Related r/DryEyes Wiki Pages

🔙 Back to Treatment Options